1,160 Shares in Anika Therapeutics, Inc. (NASDAQ:ANIK) Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC bought a new position in Anika Therapeutics, Inc. (NASDAQ:ANIKGet Rating) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,160 shares of the biotechnology company’s stock, valued at approximately $29,000.

Several other large investors have also made changes to their positions in the company. Point72 Hong Kong Ltd acquired a new stake in Anika Therapeutics in the 4th quarter valued at $39,000. Connors Investor Services Inc. increased its holdings in Anika Therapeutics by 24.2% in the 4th quarter. Connors Investor Services Inc. now owns 7,699 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 1,500 shares in the last quarter. Riverwater Partners LLC acquired a new stake in Anika Therapeutics in the 4th quarter valued at $326,000. Yousif Capital Management LLC acquired a new stake in Anika Therapeutics in the 4th quarter valued at $446,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in Anika Therapeutics in the 4th quarter valued at $545,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Anika Therapeutics Stock Performance

Shares of NASDAQ ANIK opened at $23.36 on Monday. Anika Therapeutics, Inc. has a 1 year low of $19.95 and a 1 year high of $45.81. The stock’s 50-day simple moving average is $22.30 and its 200-day simple moving average is $25.33. The firm has a market cap of $339.75 million, a price-to-earnings ratio of -212.34 and a beta of 1.02.

Anika Therapeutics (NASDAQ:ANIKGet Rating) last posted its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.13. Anika Therapeutics had a negative return on equity of 0.92% and a negative net margin of 1.09%. The company had revenue of $36.69 million for the quarter, compared to the consensus estimate of $33.90 million. During the same period in the previous year, the business earned $0.06 EPS. As a group, research analysts predict that Anika Therapeutics, Inc. will post -0.55 EPS for the current year.

Insider Activity at Anika Therapeutics

In other news, EVP David Colleran purchased 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average cost of $21.37 per share, with a total value of $32,055.00. Following the transaction, the executive vice president now owns 9,867 shares in the company, valued at approximately $210,857.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.03% of the company’s stock.

About Anika Therapeutics

(Get Rating)

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.

Read More

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Want More Great Investing Ideas?

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.